Aktis Oncology, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
AKTS$16.37+3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except shares and par value data)
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $371,630 | $37,784 |
| Marketable securities | 166,854 | 189,003 |
| Prepaid expenses and other current assets | 5,456 | 3,523 |
| Total current assets | 543,940 | 230,310 |
| Property and equipment, net | 15,295 | 14,595 |
| Operating lease right-of use assets | 12,816 | 12,651 |
| Restricted cash equivalents | 1,149 | 1,149 |
| Other assets | 3,601 | 6,180 |
| Total assets | $576,801 | $264,885 |
| Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $1,227 | $1,737 |
| Accrued expenses and other current liabilities | 6,298 | 9,522 |
| Deferred revenue, current portion | 18,958 | 18,662 |
| Operating lease liabilities, current portion | 1,430 | 1,315 |
| Total current liabilities | 27,913 | 31,236 |
| Deferred revenue, net of current portion | 32,633 | 36,156 |
| Operating lease liabilities, net of current portion | 10,147 | 10,233 |
| Total liabilities | 70,693 | 77,625 |
| Commitments and contingencies (Note 13) | ||
| Redeemable convertible preferred stock: | ||
| Series Seed redeemable convertible preferred stock, $0.0001 par value; no shares and 5,000,000 shares authorized, issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | 5,000 |
| Series A redeemable convertible preferred stock, $0.0001 par value; no shares and 78,067,500 shares authorized, issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | 145,050 |
| Series A-1 redeemable convertible preferred stock, $0.0001 par value; no shares and 2,500,000 shares authorized, issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | 8,197 |
| Series B redeemable convertible preferred stock, $0.0001 par value; no shares and 43,750,000 shares authorized, issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | 174,654 |
| Partner redeemable convertible preferred stock, $0.0001 par value; no shares and 250,000 shares authorized, issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | 508 |
| Stockholders' deficit: | ||
| Common stock, $0.0001 par value; 480,000,000 and 156,800,000 shares authorized as of March 31, 2026 and December 31, 2025, respectively; 53,403,173 shares and 915,261 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 5 | — |
| Class A Common stock, $0.0001 par value; 10,000,000 and no shares authorized as of March 31, 2026 and December 31, 2025, respectively; 1,872,829 shares and no shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | — |
| Additional paid-in capital | 681,233 | 10,373 |
| Accumulated other comprehensive (loss) income | (241) | 42 |
| Accumulated deficit | (174,889) | (156,564) |
| Total stockholders' equity (deficit) | 506,108 | (146,149) |
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | $576,801 | $264,885 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.